Ignite Creation Date:
2024-05-06 @ 4:04 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04855045
Status:
UNKNOWN
Last Update Posted:
2022-03-25
First Post:
2021-04-13
Brief Title:
An Open-label Dose Escalation and Double-masked Randomized Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children 8 Years of Age With LCA10 Caused by Mutations in the CEP290 Gene
Sponsor:
Organization:
ProQR Therapeutics
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
15
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: